Serbülent YİĞİT, Ayşe Feyda NURSAL, Özge GÜMÜŞAY, Akın TEKCAN, Serkan YILDIZ, Mehmet Kemal TÜMER

C Deletion in Exon 4 Codon 63 of p53 Gene in Turkish Patients with Oral Squamous Cell Carcinoma

OBJECTIVE Oral squamous cell carcinoma (OSCC) is the most frequently seen oral malignancy and accounts for up to 80-90% of all malignant neoplasms that occurin the oral cavity. The p53 tumor suppressor gene plays a crucial role in the regulation of the cell cycle. Mutations of the p53 gene havean important role in OSCC carcinogenesis. In this study, we aimed to evaluate the C-deletion mutation in exon 4 codon 63 of p53 gene in Turkish patients with OSCC. METHODS A total of 60 subjects were enrolled in this study, 30 patients with a pathologic diagnosis of OSCC and 30 cases of age and sex-matched healthy controls. Genotyping was performed for all individuals using polymerase chain reaction (PCR) analysis. RESULTS CONCLUSION T he findings showed that the distribution of p53 exon 4 codon 63 C-deletion was significantly different between patient group and control group (p=0.000). It was detected that all patients had C-deletion mutation in exon 4 codon 63 of p53. Our results suggest that C-deletion in exon 4 codon 63 deletion of the p53 gene may play a role in the pathogenesis of human OSCC in a Turkish cohort.

PDF

___

1. Nagpal JK, Das BR. Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management. Oral Oncol 2003;39(3):213–21.
2. Johnson NW, Jayasekara P, Amarasinghe AA. Squamous cell carcinoma and precursor lesions of the oral cavity: epidemiology and etiology. Periodontol 2000 2011;57(1):19–37.
3. Liao PH, Chang YC, Huang MF, Tai KW, Chou MY. Mutation of p53 gene codon 63 in saliva as a molecular marker for oral squamous cell carcinomas. Oral Oncol 2000;36(3):272–6.
4. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358(6381):15–6.
5. Athar M, Elmets CA, Kopelovich L. Pharmacological activation of p53 in cancer cells. Curr Pharm Des 2011;17(6):631–9.
6. Ara N, Atique M, Ahmed S, Ali Bukhari SG. Frequency of p53 gene mutation and protein expression in oral squamous cell carcinoma. J Coll Physicians Surg Pak 2014;24(10):749–53.
7. Sukhija H, Krishnan R, Balachander N, Raghavendhar K, Ramadoss R, Sen S. C-deletion in exon 4 codon 63 of p53 gene as a molecular marker for oral squamous cell carcinoma: A preliminary study. Contemp Clin Dent 2015;6(Suppl 1):S227–34.
8. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9(4):138–41.
9. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10(9):1054–72.
10. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265(5170):346–55.
11. Lazarus P, Stern J, Zwiebel N, Fair A, Richie JP Jr, Schantz S. Relationship between p53 mutation incidence in oral cavity squamous cell carcinomas and patient tobacco use. Carcinogenesis 1996;17(4):7339.
12. Hsieh LL, Wang PF, Chen IH, Liao CT, Wang HM, Chen MC, et al. Characteristics of mutations in the p53 gene in oral squamous cell carcinoma associated with betel quid chewing and cigarette smoking in Taiwanese. Carcinogenesis 2001;22(9):1497–503.
13. Zanaruddin SN, Yee PS, Hor SY, Kong YH, Ghani WM, Mustafa WM, et al. Common oncogenic mutations are infrequent in oral squamous cell carcinoma of Asian origin. PLoS One 2013;8(11):e80229.
14. Lapke N, Lu YJ, Liao CT, Lee LY, Lin CY, Wang HM, et al. Missense mutations in the TP53 DNA-binding domain predict outcomes in patients with advanced oral cavity squamous cell carcinoma. Oncotarget 2016;7(28):44194–210.